Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.47 |
| ▸ | PTGIR | P43119 | 2/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135235 | 0.89 | PTGDR2 (0.50) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL12893455 | 0.89 | PTGDR2 (0.49) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL152578 | 0.84 | PTGDR2 (0.65) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL12197430 | 0.81 | TRPM8 (0.47) | PTGDR2ALDH1A1FFAR4MEN1MAPK1 | |
| SCHEMBL136538 | 0.81 | PTGDR2 (0.42) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL3252019 | 0.80 | CYP3A4 (0.47) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL136551 | 0.80 | CYP1A2 (0.46) | CYP3A4ALDH1A1RAB9AMEN1HTT | |
| SCHEMBL137989 | 0.79 | PTGDR2 (0.55) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL137490 | 0.78 | PTGDR2 (0.78) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR | |
| SCHEMBL135232 | 0.78 | PTGDR2 (0.47) | PTGDR2CYP3A4CYP2C9TBXA2RPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-8362044-B2 | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120058123-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110039852-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP3A4 882/4885CYP2C9 690/4885 |
| US-20110039852-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP3A4 882/4885CYP2C9 690/4885 |
| US-20120058123-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CYP3A4 882/4885CYP2C9 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.